ACC

**ACC** is an experimental FcRn-targeting monoclonal antibody–interleukin-2 fusion protein developed for **lupus nephritis**. The FcRn-antibody component is intended to antagonize neonatal Fc receptor-mediated IgG recycling and thereby reduce circulating pathogenic IgG and autoantibodies, while the IL-2 component provides cytokine signaling intended to preserve regulatory T-cell function. In an MRL/lpr mouse model, ACC reduced anti-dsDNA antibodies, renal IgG/C3 deposition, plasma-cell and effector T-cell populations, and histopathologic renal injury; it was also reported to have improved stability and renal accumulation relative to conventional IL-2. The available evidence is limited to a preclinical meeting abstract and does not establish clinical efficacy or safety in humans. ([asn-online.org](https://www.asn-online.org/education/kidneyweek/2025/program-abstract.aspx?controlId=4352708))

Other names

FcRn monoclonal antibody-IL-2 fusion proteinIL-2-FcRn monoclonal antibody fusion proteinIL2-FcRn monoclonal antibody fusion proteinIL 2-FcRn monoclonal antibody fusion protein